Study summary · research use only
Treatment of Kaposi's sarcoma with human chorionic gonadotropin
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This paper reviewed the use of human chorionic gonadotropin (hCG) preparations in treating Kaposi's sarcoma (KS), a condition affecting humans. The authors noted that clinical-grade hCG preparations have been reported as toxic to KS cells, but that the mechanism of this anti-KS activity remains unclear, and that results from clinical studies using commercial hCG preparations in human KS have been highly contradictory. The authors suggested this inconsistency may reflect varying proportions of pro-KS and anti-KS components across different hCG preparations, some of which might lack anti-KS activity or contain contaminating KS growth factors, and advised caution in the use of crude hCG preparations for treating KS.
Abstract
Clinical-grade preparations of human chorionic gonadotropin (hCG) have been shown to be toxic to Kaposi's sarcoma (KS) cells. However, the mechanism of the anti-KS activity achieved with these preparations remains unclear. The results of clinical studies using commercial hCG preparations in human KS are also highly contradictory. The apparent controversy between different studies may be due to the fact that pro- and anti-KS components are present in varying proportions in different hCG preparations. As certain hCG preparations could not only lack the ability to control KS but also contain some contaminant KS growth factor(s), we suggest a cautious use of crude hCG for the treatment of KS.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.